Processa Pharmaceuticals Announces Share Offering
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), a visionary company dedicated to the advancement of Next Generation Cancer (NGC) therapies, has officially priced a significant public offering. This strategic move entails issuing 28,000,000 shares of its common stock, accompanied by warrants allowing for the purchase of an equivalent number of shares. The offering has been priced at a competitive $0.25 per share, providing an appealing option for investors interested in the cancer treatment sector.
Details of the Offering
Pricing and Structure
The pricing structure of this public offering includes pre-funded warrants replacing some common stock shares, further broadening the accessibility for potential investors. Each common warrant is priced at $0.25, is immediately exercisable upon issuance, and is valid for a period of five years. This offering is set to close shortly, pending the customary conditions being met.
Fund Utilization
From this offering, Processa Pharmaceuticals expects to raise approximately $7 million in gross proceeds. These funds will play a crucial role in advancing the ongoing Phase 2 clinical trial for their innovative therapy, NCG-Cap. Additionally, the proceeds will cover working capital needs and broader corporate purposes, ensuring the company stays on track in its mission to revolutionize cancer treatments.
Role of H.C. Wainwright & Co.
H.C. Wainwright & Co. serves as the exclusive placement agent for this public offering, bringing expertise and strategic support to help facilitate the transaction efficiently.
Registration and Regulatory Aspects
Compliance with SEC Regulations
A registration statement related to this offering was filed with the Securities and Exchange Commission (SEC) and has been declared effective. Investors can expect a full prospectus to accompany the offering, ensuring they are well-informed about the supporting details and risks involved.
About Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. is a pioneering clinical-stage pharmaceutical company committed to developing Next Generation Cancer therapies. Their focus lies on enhancing existing FDA-approved oncology drugs, manipulating them to improve safety and efficacy while maintaining their cancer-killing properties. This innovative approach aims to provide enhanced therapies that offer better tolerability and outcomes for cancer patients.
Company Engagement
Contact Information
For inquiries regarding the offering or company updates, individuals can reach out to: Patrick Lin at (925) 683-3218 or via email at plin@processapharma.com. Additional information about Processa Pharmaceuticals and their groundbreaking work can be found on their website, www.processapharma.com.
Frequently Asked Questions
What is the main goal of Processa Pharmaceuticals?
Processa Pharmaceuticals aims to develop innovative cancer therapies that improve safety and efficacy compared to traditional treatments.
How much is Processa raising through this offering?
The company is raising $7 million through its public offering to support its Phase 2 clinical trials and other operational needs.
What is the pricing of the offering?
The offering is priced at $0.25 per share, including pre-funded warrants and common warrants for the same amount of shares.
Who is acting as the placement agent for this offering?
H.C. Wainwright & Co. is serving as the exclusive placement agent for Processa’s public offering.
What will the raised funds be used for?
The funds from this offering will mainly go towards continuing clinical trials for NCG-Cap and broader company operations.
